The first patients in the United States have been treated using the OrbusNeich Teleport Microcatheter (Teleport; Cardiovascular Systems), which recently received US Food and Drug Administration (FDA) 510(k) clearance.
Microcatheters are used to provide support and safe guidewire exchange during complex cardiovascular procedures. Teleport is a microcatheter designed for deliverability and support, with a tip designed to enable access in the most challenging lesions.
Annapoorna S Kini, director of the Cardiac Catheterization Laboratory at Mount Sinai Medical Center, New York, USA, and Emmanouil Brilakis, interventional cardiologist at Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, USA, treated the first patients in the United States with Teleport.
Kini said, “I am excited and honoured to be the first to use Teleport microcatheter in the United States. Teleport allowed me to deliver the microcatheter easily through tortuous coronary vasculature while maintaining catheter position for guidewire exchange treating a complex chronic total occlusion.”
Brilakis added, “I had the opportunity to use the Teleport Microcatheter in Europe and was impressed by its balance of deliverability and support. Teleport’s robust tip design is unique, enabling access to tight lesions while providing the torqueability necessary to treat very challenging lesions. I’m excited to have this device available to treat my patients here in the United States.”
Scott Ward, CSI’s Chairman, president and chief executive officer, said, “We are committed to building a comprehensive cardiovascular company and leveraging our commercial footprint and clinical value to become the partner of choice in the revascularisation of patients with complex peripheral and coronary artery disease.”